Amrutanjan Health Care
- P/E
- 27.49
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 24.80%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹18.67
- Book Value
- ₹128.06
- Market Cap
- —
- P/E (TTM)
- 27.49
- P/B
- 4.01
- ROE
- 18.40%
- Dividend Yield
- 0.98%
- EBITDA
- ₹36.50 Cr
- 52W High
- ₹744.00
- 52W Low
- ₹476.50
- Day Range
- ₹505.05 – ₹526.90
- Volume
- 96,819
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Amrutanjan Health Care (this company) | ₹513.30 | 27.49 | ₹1,491 Cr | 4.01 | 0.98% | 18.40% | 24.80% | ₹511 Cr | ₹54 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.70% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 58
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 54
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 39
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 29
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 26.7%
- Company's working capital requirements have reduced from 122 days to 93.8 days
Weaknesses
2- The company has delivered a poor sales growth of 8.59% over past five years.
- Promoter holding has decreased over last 3 years: -4.07%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 6 | 7 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bearish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 59.18
- Neutral
- MACD (12,26,9)
- −1.76
- Bullish
- SMA (50)
- 504.00
- Bullish
- SMA (200)
- 542.61
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +11.20% |
|---|---|
| 5Y | +8.60% |
| 3Y | +9.80% |
| 1Y | +11.28% |
| TTM | +10.68% |
Net profit
| 10Y | +10.18% |
|---|---|
| 5Y | −1.00% |
| 3Y | +13.19% |
| 1Y | +13.73% |
| TTM | −1.05% |
Operating cash flow
| 10Y | +5.54% |
|---|---|
| 5Y | −16.93% |
| 3Y | +21.64% |
| 1Y | −29.41% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −3.28 pp |
|---|---|
| 5Y | −7.41 pp |
| 3Y | +3.27 pp |
| 1Y | +2.28 pp |
| TTM | +0.72 pp |
Revenue by year
| Mar 2017 | ₹207 Cr |
|---|---|
| Mar 2018 | ₹220 Cr |
| Mar 2019 | ₹253 Cr |
| Mar 2020 | ₹261 Cr |
| Mar 2021 | ₹333 Cr |
| Mar 2022 | ₹406 Cr |
| Mar 2023 | ₹380 Cr |
| Mar 2024 | ₹421 Cr |
| Mar 2025 | ₹452 Cr |
| Mar 2026 | ₹503 Cr |
Net profit by year
| Mar 2017 | ₹22.00 Cr |
|---|---|
| Mar 2018 | ₹20.00 Cr |
| Mar 2019 | ₹25.00 Cr |
| Mar 2020 | ₹25.00 Cr |
| Mar 2021 | ₹61.00 Cr |
| Mar 2022 | ₹67.00 Cr |
| Mar 2023 | ₹40.00 Cr |
| Mar 2024 | ₹45.00 Cr |
| Mar 2025 | ₹51.00 Cr |
| Mar 2026 | ₹58.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 77.86 | 99.31 | 117 | 127 | 83.74 | 110 | 123 | 135 | 94.05 | 118 | 141 | 150 | 103 | 135 |
| Expenses | 70.71 | 92.47 | 95.42 | 111 | 80.19 | 96.32 | 99.4 | 118 | 85.61 | 101 | 116 | 124 | 96.73 | 112 |
| Operating Profit | 7.15 | 6.84 | 21.57 | 16.24 | 3.55 | 13.6 | 23.35 | 17.7 | 8.44 | 16.52 | 25.17 | 25.55 | 6.24 | 23.61 |
| OPM % | 9.18% | 6.89% | 18.44% | 12.78% | 4.24% | 12.37% | 19.02% | 13.07% | 8.97% | 14.04% | 17.85% | 17.06% | 6.06% | 17.47% |
| Other Income | 3.69 | 3.95 | 3.76 | 4.95 | 4.45 | 4.05 | 4.36 | 4.82 | 4.43 | 4.3 | 2.87 | −2.88 | 1.78 | 3.02 |
| Interest | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 |
| Depreciation | 1.39 | 1.55 | 1.58 | 1.53 | 1.59 | 1.65 | 1.66 | 1.62 | 1.53 | 1.56 | 1.62 | 1.61 | 1.92 | 3.49 |
| PBT | 9.43 | 9.21 | 23.7 | 19.61 | 6.35 | 15.94 | 25.99 | 20.86 | 11.29 | 19.21 | 26.36 | 21.02 | 6.07 | 23.1 |
| Tax % | 25.56% | 25.62% | 26.41% | 30.34% | 27.24% | 25.97% | 25.93% | 27.23% | 26.4% | 27.33% | 26.2% | 22.94% | 28.05% | 25.19% |
| Net Profit | 7.01 | 6.85 | 17.45 | 13.66 | 4.62 | 11.8 | 19.25 | 15.18 | 8.31 | 13.96 | 19.45 | 16.19 | 4.37 | 17.28 |
| EPS (₹) | 2.4 | 2.37 | 6.04 | 4.72 | 1.6 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.6 | 1.51 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 503 | 511 |
| Expenses | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 427 | 438 |
| Operating Profit | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 76 | 73 |
| OPM % | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 15% | 14% |
| Other Income | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 9 | 6 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 |
| PBT | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 78 | 73 |
| Tax % | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | 26% | — |
| Net Profit | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 58 | 54 |
| EPS (₹) | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 20.03 | 18.67 |
| Div. Payout % | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% | 24% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 367 |
| Borrowings | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
| Other Liabilities | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 | 137 |
| Total Liabilities | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
| Fixed Assets | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 | 51 |
| CWIP | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 | 106 |
| Investments | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 | 3 |
| Other Assets | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 349 |
| Total Assets | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 19 | 21 | 8 | 19 | 21 | 18 | 91 | 52 | 20 | 28 | 51 | 36 |
| Investing | −5 | 1 | 0 | −8 | −11 | −14 | −88 | −36 | −2 | 19 | −31 | −21 |
| Financing | −12 | −11 | −5 | −9 | −7 | −12 | −7 | −17 | −15 | −48 | −13 | −14 |
| Net Cash Flow | 2 | 12 | 3 | 2 | 3 | −7 | −4 | −1 | 3 | −1 | 6 | 1 |
| Free Cash Flow | 13 | 20 | 5 | 18 | 19 | 16 | 89 | 29 | 11 | 21 | 15 | −19 |
| CFO/EBITDA | 114 | 104 | 77 | 105 | 101 | 95 | 146 | 96 | 81 | 86 | 118 | 72 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 | 44 |
| Inventory Days | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 | 56 |
| Days Payable | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 | 106 |
| Cash Conversion Cycle | 61 | 48 | −15 | −16 | 0 | 13 | −41 | −35 | −6 | −5 | −23 | −6 |
| Working Capital Days | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 | 94 |
| ROCE % | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% | 25% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Amrutanjan Health Care insights
70 extracted metrics across FY10–FY27.
Documents
- 12 Nov 2024
- 23 May 2024
- 31 Jul 2026
- 28 Mar 2022
- 8 Mar 2022
- 26 Nov 2021
- 22 Nov 2021
Frequently Asked Questions about Amrutanjan Health Care
What does Amrutanjan Health Care Ltd do?
Where is Amrutanjan Health Care Ltd (AMRUTANJAN) listed?
Which sector does Amrutanjan Health Care Ltd belong to?
What is the PE ratio of Amrutanjan Health Care Ltd?
What is the 52-week high and low of Amrutanjan Health Care Ltd?
Does Amrutanjan Health Care Ltd pay dividends?
What is the Return on Equity (ROE) of Amrutanjan Health Care Ltd?
Company Information
AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AMRUTANJAN.md for Amrutanjan Health Care Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.